Join Marks & Clerk, One Nucleus and 59 North for a breakfast networking event and panel discussion during London Life Science Week.

In today's biotech market, breakthrough science alone is no longer enough. Investors, strategic partners and acquirers are placing greater emphasis on intellectual property as a key indicator of value, defensibility and long-term commercial potential.
Bringing together biotech founders, investors, pharmaceutical business development leaders and IP specialists, this discussion will examine how intellectual property influences fundraising outcomes, deal making and competitive positioning throughout a company's growth journey.

The panel will share practical insights into what investors and partners look for during diligence, how to build an IP strategy that supports enterprise value, and how emerging developments such as AI and changing global regulatory frameworks are reshaping innovation and ownership.
The session will conclude with an audience Q&A and networking.

Panel
•    Confirmed: Mike Ward, Chair. Life Science Consultant
•    Confirmed: Will Arends, Partner, Marks & Clerk
•    Confirmed: Sten Sorensen, CEO, Cereno Scientific
Further panel members to be announced soon

Registration: Is being handled by Marks & Clerk HERE.

This event is delivered in collaboration with...